Overview of clear cell renal cell carcinoma: from mechanisms to clinical.

Authors

Han Yang, Xingda Zhang, Qingming Ji, Xia Sheng

Published in

Frontiers in medicine. Volume 13. Pages 1822724. Epub Jun 24, 2026.

Abstract

Clear cell renal cell carcinoma is the most common histological subtype of kidney cancer, and its development is often related to mutations in the VHL gene. Inactivation of the VHL gene leads to accumulation of HIF-2α. The accumulation of HIF-2α activates multiple signaling pathways, promoting tumor growth and proliferation. The treatment strategies for clear cell renal cell carcinoma mainly include surgical resection, targeted drugs, and immune checkpoint inhibitors. Previous targeted treatments have mostly been tyrosine kinase inhibitors. In recent years, the HIF-2α inhibitor Belzutifan has been approved by the FDA for the treatment of clear cell renal cell carcinoma due to its specificity in blocking the HIF-2α signaling pathway and its ability to inhibit tumor growth. This article, based on HIF-2α, provides an overview of the pathogenesis, diagnosis, and treatment of clear cell renal cell carcinoma, with a focus on the clinical trial results of Belzutifan, offering direction and information for the clinical treatment of clear cell renal cell carcinoma.

PMID:
42422841
Bibliographic data and abstract were imported from PubMed on 09 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.